Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | STS | P08842 | 2/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | BMP1 | P13497 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30708255 | 0.91 | JAK2 (0.35) | JAK2JAK1EPHX2GPR119KRAS | |
| SCHEMBL30708428 | 0.90 | GPR119 (0.34) | JAK2JAK1EPHX2GPR119KRAS | |
| SCHEMBL21733830 | 0.87 | GPR119 (0.38) | EPHX2GPR119KRASBMP1KDM4E | |
| SCHEMBL21733788 | 0.86 | KRAS (0.44) | GPR119KRAS | |
| SCHEMBL30708429 | 0.86 | KRAS (0.36) | JAK2JAK1EPHX2GPR119KRAS | |
| SCHEMBL30708433 | 0.86 | KRAS (0.36) | JAK2JAK1EPHX2GPR119KRAS | |
| SCHEMBL30708280 | 0.86 | KRAS (0.36) | JAK2JAK1EPHX2GPR119KRAS | |
| SCHEMBL30708465 | 0.83 | KRAS (0.35) | KRASPRMT5KDM4EALDH1A1HPGD | |
| SCHEMBL30708297 | 0.83 | KRAS (0.35) | KRASPRMT5KDM4EALDH1A1HPGD | |
| SCHEMBL30708350 | 0.83 | KRAS (0.35) | KRASPRMT5KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547666-A1 | METHODS FOR TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024006445-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2024-01-04 | — | — | WO | disclosed |